

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

~~XXXXXXXXXXXXXXXXXXXX~~

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/Caplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of Caplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/Caplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS EXPRESS			DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:27:57 ON 05 DEC 2005

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:28:12 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6
DICTIONARY FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10526938.str

```

chain nodes :
9 10 11 12 13 14 16 17 18 19 20 21 22 23 24 25 26 27 32 35
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-16 6-9 9-10 10-11 11-12 12-13 13-14 13-17 14-32 14-35 18-22 18-21
18-35 19-23 19-20 19-32 20-25 21-24 24-26 25-27
ring bonds :
1-2 1-3 2-4 3-5 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-3 1-16 2-4 3-5 4-5 4-6 5-8 6-7 7-8 13-14 13-17 18-22 18-21
19-23 19-20
exact bonds :
6-9 9-10 10-11 11-12 12-13 14-32 14-35 18-35 19-32 20-25 21-24 24-26
25-27
isolated ring systems :
containing 1 :

```

G1: O, NH

Match level :


```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
32:CLASS 35:CLASS
```

L1 STRUCTURE UPLOADED

$$\Rightarrow d_{11}$$

L1 HAS NO ANSWERS

L1 STR



G1 O, NH

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:28:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 151 TO ITERATE

100.0% PROCESSED 151 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2283 TO 3757
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 12:28:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3292 TO ITERATE

100.0% PROCESSED 3292 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L3 13 SEA SSS FUL L1

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 12:28:56 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 5 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 4 Dec 2005 (20051204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 1 L3

=> d l1 ibib abs hitstr tot

L1 HAS NO ANSWERS

'IBIB ABS HITSTR ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains
data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains
data.

SDA ----- All Structure Data (image, attributes, connection table and
map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220338 CAPLUS

DOCUMENT NUMBER: 140:271147

TITLE: Multipurpose biotin-containing linker compounds and
ligands containing oligosaccharides and biotin and
process for producing the same

INVENTOR(S): Suda, Yasuo; Arano, Akio; Hayashi, Hideki; Kusumoto,
Shoichi; Sobel, Michael

PATENT ASSIGNEE(S): Japan Science and Technology Corporation, Japan; Japan
as Represented by the President of Kagoshima
University

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004022565	A1	20040318	WO 2003-JP9973	20030806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			
	GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS,			
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,			
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,			
	TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 JP 2004155762 A2 20040603 JP 2003-190637 20030702
 CA 2500197 AA 20040318 CA 2003-2500197 20030806
 EP 1548016 A1 20050629 EP 2003-794076 20030806
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: JP 2002-263414 A 20020909
 JP 2003-190637 A 20030702
 WO 2003-JP9973 W 20030806
 OTHER SOURCE(S): MARPAT 140:271147
 GI






AB Disclosed is a multipurpose linker compound having a structure represented by the following general formula (I) (wherein Y has a structure represented by O or NH; X has a multibranched site structure involving 4 hydrocarbon derivative chains each having an aromatic amino group at the end and optionally having a carbon-nitrogen bond in the main chain). This multipurpose linker compound makes it possible to two-dimensionally align saccharide mols. at a high reproducibility on the surface of a support for protein anal. Also disclosed is a ligand in which saccharide mols. have been introduced into the above-described multipurpose linker compound. Also claimed are a sensor chip for detecting the interaction of oligosaccharides by surface plasmon resonance or affinity chromatog. column in which the above biotin-linked oligosaccharide ligands are introduced and fixed on the surface of a support having streptavidin or avidin immobilized. Thus, reductive amination of a biotin-containing linker (II; R = H) with glucose, maltose, or lactose using sodium cyanoborohydride in aqueous AcOH/MeOH gave ligands II (R = Q; R1 = OH, α -D-glucopyranosyloxy, or β -D-galactopyranosyloxy). The latter two ligands, i.e. II (R = Q; R1 = OH) and II (R = Q, R1 = α -D-glucopyranosyloxy) were introduced on a sensor chip comprising a avidin (NeutrAvidin)-linked gold thin film vapor-deposited on a glass substrate and their interaction with Con A was studied using surface plasmon resonance.

IT 672295-58-8DP, bound on Hitrap NHS-activated Hp
 RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
 (affinity column; preparation of multipurpose biotin-containing linkers and ligands containing oligosaccharides and biotin for affinity chromatog. column and sensor chips in protein anal. by surface plasmon resonance)
 RN 672295-58-8 CAPLUS
 CN D-Glucitol, 1,1',1'',1'''-[[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]imino]bis[(1-oxo-3,1-propanediyl)imino-2,1-ethanediyl]nitrilobis[(1-oxo-3,1-propanediyl)imino-3,1-phenyleneimino]]]tetrakis[1-deoxy-4-O- α -D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





chain nodes :
 9 10 11 12 13 14 16 17
 ring nodes :
 1 2 3 4 5 6 7 8
 chain bonds :
 1-16 6-9 9-10 10-11 11-12 12-13 13-14 13-17
 ring bonds :
 1-2 1-3 2-4 3-5 4-5 4-6 5-8 6-7 7-8
 exact/norm bonds :
 1-2 1-3 1-16 2-4 3-5 4-5 4-6 5-8 6-7 7-8 13-14 13-17
 exact bonds :
 6-9 9-10 10-11 11-12 12-13
 isolated ring systems :
 containing 1 :

G1:O,NH

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 O,NH

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 4 Dec 2005 (20051204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l10

L11 3493 L10

=> s l11 and branched

71123 BRANCHED

1 BRANCHEDS

71124 BRANCHED

(BRANCHED OR BRANCHEDS)

L12 29 L11 AND BRANCHED

=> s l11 and branch?

177082 BRANCH?

L13 39 L11 AND BRANCH?

=> s l13 and (sugar or monosaccharide or oligosaccharide or polysaccharide)

244646 SUGAR

127419 SUGARS

314549 SUGAR

(SUGAR OR SUGARS)

10755 MONOSACCHARIDE

17112 MONOSACCHARIDES

22171 MONOSACCHARIDE

(MONOSACCHARIDE OR MONOSACCHARIDES)

28090 OLIGOSACCHARIDE

42337 OLIGOSACCHARIDES

50713 OLIGOSACCHARIDE

(OLIGOSACCHARIDE OR OLIGOSACCHARIDES)

56209 POLYSACCHARIDE

69948 POLYSACCHARIDES

88511 POLYSACCHARIDE

(POLYSACCHARIDE OR POLYSACCHARIDES)

L14 5 L13 AND (SUGAR OR MONOSACCHARIDE OR OLIGOSACCHARIDE OR POLYSACCHARIDE)

=> s l11 and ?branch?

186071 ?BRANCH?

L15 40 L11 AND ?BRANCH?

=> s l15 and (sugar or monosaccharide or oligosaccharide or polysaccharide)

244646 SUGAR

127419 SUGARS

314549 SUGAR

(SUGAR OR SUGARS)

10755 MONOSACCHARIDE

17112 MONOSACCHARIDES

22171 MONOSACCHARIDE

(MONOSACCHARIDE OR MONOSACCHARIDES)

28090 OLIGOSACCHARIDE

42337 OLIGOSACCHARIDES

50713 OLIGOSACCHARIDE

(OLIGOSACCHARIDE OR OLIGOSACCHARIDES)

56209 POLYSACCHARIDE
69948 POLYSACCHARIDES
88511 POLYSACCHARIDE
(POLYSACCHARIDE OR POLYSACCHARIDES)

L16 6 L15 AND (SUGAR OR MONOSACCHARIDE OR OLIGOSACCHARIDE OR POLYSACCHARIDE)

=> s l16 not l4
L17 5 L16 NOT L4

=> d l17 ibib abs hitstr tot

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:146298 CAPLUS
TITLE: **Oligosaccharide** mimics containing galactose and fucose specifically label tumour cell surfaces and inhibit cell adhesion to fibronectin
AUTHOR(S): Kim, Evelyn Y.-L.; Gronewold, Claas; Chatterjee, Amitava; Von der Lieth, Claus-Wilhelm; Kliem, Christian; Schmauser, Birgit; Wiessler, Manfred; Frei, Eva
CORPORATE SOURCE: Molecular Toxicology, Deutsches Krebsforschungszentrum, Heidelberg, 69120, Germany
SOURCE: ChemBioChem (2005), 6(2), 422-431
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

AB With the aim of establishing a versatile and easy synthesis of **branched** saccharides for biol. applications, we used mol.-dynamics simulations to model Lewisy to two classes of diol triantennary saccharide mimetics. One set of mimetics was based on 1,3,5-tris(hydroxymethyl)cyclohexane (TMC) as the core, the other on furan, and both were derivatized with galactose and/or fucose. The TMC-based saccharides were biotinylated, while the furan disaccharides were treated with maleimide-activated biotin in a Diels-Alder fashion to yield oxazatricyclodecanes (OTDs). These were then assayed as cell-surface labels in human colon (SW480 and CaCo-2), liver (PLC), Glia (U333 CG 343) and ovary (SKOV-3) tumor cell lines. Discrete staining patterns were observed in all cells, usually at one or two poles of the cells, particularly with the asym. 3- β -L-fucopyranosyloxymethyl-4- β -D-galactopyranosyloxymethyl-OTD. Normal SV40-transformed fibroblasts (SV80) showed no staining. Adhesion of the highly metastatic mouse melanoma line B16F10 to fibronectin was inhibited by 80% by the TMC-digalactoside and by 30% by 3,4-bis-(β -D-galactopyranosyloxymethyl)furan. None of the saccharide mimetics inhibited the adhesion of the less metastatic B16F1 line. Migration of B16F10 cells through Matrigel was greatly inhibited by the TMC-digalactoside and weakly inhibited by the TMC-trigalactoside. The saccharide mimetics that had shown the best structural agreements with the terminal saccharides of Lewisy in the mol. dynamics simulation were also the most biol. potent compds.; this underlines the predictive nature of mol. dynamics simulations. The use of the non-saccharide cores enabled us to adapt spacer lengths and terminal saccharides to optimize the structures to bind more avidly to cell-surface lectins.


IT INDEXING IN PROGRESS
IT 869202-33-5 869202-34-6 869202-35-7
869202-36-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(preparation and mol. dynamics simulation of **oligosaccharide** mimetics containing galactose and fucose and characterization of tumor cell surface labeling and inhibition of cell adhesion to fibronectin)

RN 869202-33-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 869202-34-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 869202-35-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 869202-36-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A





IT 72040-63-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and mol. dynamics simulation of **oligosaccharide** mimetics containing galactose and fucose and characterization of tumor cell surface labeling and inhibition of cell adhesion to fibronectin)

RN 72040-63-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:566663 CAPLUS

DOCUMENT NUMBER: 141:106736

TITLE: Three-**branched sugar**-chain asparagine derivatives, the **sugar**-chain asparagines, the **sugar** chains, and processes for producing these

INVENTOR(S): Kajihara, Yasuhiro; Kakehi, Kazuaki; Fukae, Kazuhiro

PATENT ASSIGNEE(S): Otsuka Chemical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058824	A1	20040715	WO 2003-JP16912	20031226
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2511655	AA	20040715	CA 2003-2511655	20031226
EP 1577324	A1	20050921	EP 2003-782926	20031226
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			JP 2002-378203	A 20021226
			WO 2003-JP16912	W 20031226

OTHER SOURCE(S): MARPAT 141:106736

AB The invention relates to a three-**branched sugar**-chain asparagine derivative in which the N of an amino group of asparagine has been modified with a lipid-soluble protective group, biotin group, or FITC group; a three-**branched sugar**-chain asparagine derivative which is the three-**branched sugar**-chain asparagine derivative having at least one fucose bonded to an N-acetylglucosamine on the non-reducing end group side of the **sugar**-chain asparagine; these **sugar**-chain asparagines; and the **sugar** chains.

IT 719288-52-5P





RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of three-**branched sugar**-chain asparagine derivs.)



RN 719288-52-5 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-N2-[5-[(3aS, 4S, 6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HO...





L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:339444 CAPLUS
 DOCUMENT NUMBER: 130:343042
 TITLE: Biocompatible polymeric coatings for cell culture substrate and medical devices
 INVENTOR(S): Domb, Abraham Jacob
 PATENT ASSIGNEE(S): Alomone Labs Ltd., Israel
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

EP 914835	A2	19990512	EP 1998-309089	19981105
EP 914835	A3	20010321		
EP 914835	B1	20050824		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

IL 122153	A1	20050320	IL 1997-122153	19971110
AT 302623	E	20050915	AT 1998-309089	19981106
US 6127448	A	20001003	US 1998-189101	19981109

PRIORITY APPLN. INFO.:

IL 1997-122153 A 19971110

AB The invention provides a biocompatible polymeric coating material selected from the group consisting of linear, dendrimeric and **branched** polymers which contain primary, secondary, tertiary or quaternary amine groups with hydrophobic side chains and which polymers are insol., or only slightly soluble, in aqueous solution at pH 3-11 and soluble in at least one organic

solvent selected from the group consisting of alcs., acetone, Me Et ketone, THF, dioxane, chloroform, dichloromethane, hexanes, mixts. thereof and mixts. of any of the above with water. The invention also provides the use of such a polymeric material in a biocompatible coating composition for substrates such as a cell growth culture substrate or a medical device. The cell adhesion properties of polystyrene plates coated with various polyamine derivs. (e.g. stearyl and pentyl derivs. of polyethylenimine and polyvinylamine) were tested using PC12 neuronal cells.

IT 224312-24-7

RL: DEV (Device component use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible polymeric coatings for cell growth culture substrate and medical devices)

RN 224312-24-7 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-(2-methyl-1-oxo-2-propenyl)hydrazide, (3aS,4S,6aR)-, polymer with 2-(dimethylamino)ethyl 2-methyl-2-propenoate and dodecyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 224312-23-6

CMF C14 H22 N4 O3 S


Absolute stereochemistry.



CM 2

CRN 2867-47-2


CMF C8 H15 N O2



CM 3

CRN 142-90-5

CMF C16 H30 O2



L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:349670 CAPLUS

DOCUMENT NUMBER: 125:34044

TITLE: Preparation of tetrasaccharide conjugates as inhibitors of cell adhesion.

INVENTOR(S): Kretzschmar, Gerhard; Schmidt, Wolfgang; Sprengard, Ulrich; Bartnick, Eckart; Seiffge, Dirk; Kunz, Horst

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Ger. Offen., 31 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 4436164	A1	19960411	DE 1994-4436164	19941010
US 5858994	A	19990112	US 1995-509079	19950731
EP 714903	A1	19960605	EP 1995-115588	19951004
EP 714903	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 217630	E	20020615	AT 1995-115588	19951004
CA 2160100	AA	19960411	CA 1995-2160100	19951006
JP 08325286	A2	19961210	JP 1995-261763	19951009
PRIORITY APPLN. INFO.:			DE 1994-4436164	A 19941010
OTHER SOURCE(S):	MARPAT 125:34044			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB ZY(CH₂)_n(NHCO)pR₂ [Z = **branched** tetrasaccharide residue; Y = O, NHCO; R₂ = amino acid or oligopeptide residue, (cyclo)aliphatic residue, combination of aliphatic and heterocyclic residues, triphenylmethane dye; when Y = O and p = 1, then n = 2-10; when Y = NHCO and p = 0, n = 0-10; when Y = NHCO and p = 1, then n = 1-10], were prepared for treatment and diagnosis of diseases dependent on cell-cell adhesion, and as synthetic vaccines. Thus, title compound (I; R₁ = H-Arg-Gly-Asp-Ala-), prepared via lactone (II), inhibited HL60 cell adhesion to recombinant P-selectin with IC₅₀ = 0.01 mM.

IT **176244-96-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of tetrasaccharide conjugates as inhibitors of cell adhesion)

RN 176244-96-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 3)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]hexyl]hexahydro-2-oxo-, [3aS-(3 $\alpha\alpha$,4 β ,6 $\alpha\alpha$)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

 OH

 OH

NHAc

OH

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:837578 CAPLUS

DOCUMENT NUMBER: 123:334348

TITLE: Methods for the solid phase synthesis of glycoconjugates

INVENTOR(S): Vetter, Dirk; Tumelty, David; Antonenko, Valery

PATENT ASSIGNEE(S): Affymax Technologies N.V., Neth.

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518971	A1	19950713	WO 1995-US484	19950110
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9516029	A1	19950801	AU 1995-16029	19950110
PRIORITY APPLN. INFO.:			US 1994-179741	A 19940111
			US 1994-201607	A 19940225
			WO 1995-US484	W 19950110

OTHER SOURCE(S): CASREACT 123:334348

AB An efficient and versatile method of forming N-linked glycoconjugates is described wherein a glycosyl acceptor, typically comprising an activated carboxyl group, is reacted with a glycosylating agent, typically a glycosyl amine, in the presence of a coupling catalyst and optionally an exogenous base. Depending on the choice of reactive site, this method can be used to form N-linked glycoconjugates, in either a soluble or substrate-bound, linear or **branched** format.

IT **72040-63-2**, N-Hydroxysuccinimidyl biotinamidocaproate


RL: RCT (Reactant); RACT (Reactant or reagent)

(methods for solid-phase synthesis of glycoconjugates)

RN 72040-63-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 168636-40-6P 168636-41-7P 168636-42-8P
 168636-43-9P 168636-44-0P 168636-45-1P
 168636-46-2P 168636-47-3P 168636-48-4P
 168636-49-5P 168636-50-8P 168636-51-9P
 168636-52-0P 168636-53-1P 168636-54-2P
 168636-55-3P 168636-56-4P 168636-57-5P
 168636-58-6P 168636-59-7P 168636-60-0P
 168636-61-1P 168636-62-2P 168636-63-3P
 168636-64-4P 168636-65-5P 168636-66-6P
 168636-67-7P 168636-68-8P 168752-70-3P
 168752-71-4P 168752-72-5P 168752-73-6P
 168752-74-7P 168752-75-8P 168752-76-9P
 168752-77-0P 168752-78-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (methods for solid-phase synthesis of glycoconjugates)


RN 168636-40-6 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-(D-glucopyranosylamino)-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-41-7 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(6-deoxy-L-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)



RN 168636-42-8 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)



RN 168636-43-9 CAPLUS


CN α -Neuraminic acid, N-acetyl-2-deoxy-2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168636-44-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(N-acetylmuramosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-45-1 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-3-O-sulfo-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-46-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-6-O-sulfo-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)




RN 168636-47-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-deoxy-3-O-sulfo-2-(sulfoamino)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)




RN 168636-48-4 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)




RN 168636-49-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-phosphono-D-mannopyranosyl)amino]hexyl]-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)




RN 168636-50-8 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-sulfo-D-galactopyranosyl)amino]hexyl]-, [3aS-(3aα, 4β, 6aα)]- (9CI) (CA INDEX NAME)



RN 168636-51-9 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-α-D-glucopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα, 4β, 6aα)]- (9CI) (CA INDEX NAME)




RN 168636-52-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(O-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα, 4β, 6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 168636-53-1 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6α)]- (9CI) (CA INDEX NAME)



PAGE 1-A







RN 168636-54-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3 $\alpha\alpha$, 4 β , 6 $\alpha\alpha$)]- (9CI) (CA INDEX NAME)




RN 168636-55-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3 $\alpha\alpha$, 4 β , 6 $\alpha\alpha$)]- (9CI) (CA INDEX NAME)




RN 168636-56-4 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[[4-O-(2-O-methyl- β -D-galactopyranosyl)-D-glucopyranosyl]amino]-6-oxohexyl]-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-57-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-4-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-58-6 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aalpha,4beta,6alpha)]- (9CI) (CA INDEX NAME)




RN 168636-59-7 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-6-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aalpha,4beta,6alpha)]- (9CI) (CA INDEX NAME)




RN 168636-60-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aalpha,4beta,6alpha)]- (9CI) (CA INDEX NAME)




RN 168636-61-1 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-6-O-beta-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aalpha,4beta,6alpha)]- (9CI) (CA INDEX NAME)



RN 168636-62-2 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[6-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aalpha,4beta,6alpha)]- (9CI) (CA INDEX NAME)



RN 168636-63-3 CAPLUS


CN D-Galactopyranuronic acid, 1-deoxy-4-O-alpha-D-galactopyranuronosyl-1-

[[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-1-oxohexyl]amino]-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)



RN 168636-64-4 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(6-O- β -D-galactopyranosyl-D-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)




RN 168636-65-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3a α ,4 β ,6a α)]- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 168636-66-6 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 3)-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3 α ,4 β ,6 α)]- (9CI) (CA INDEX NAME)




RN 168636-67-7 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O- β -D-

galactopyranosyl-(1→3)-O-6-deoxy-α-L-galactopyranosyl-
 (1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-
 (1→3)-O-β-D-galactopyranosyl-(1→4)-D-
 glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-
 (3α,4β,6α)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 168636-68-8 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[(3-O-α-D-mannopyranosyl-D-mannopyranosyl)amino]-6-oxohexyl]-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-70-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-(D-galactopyranosylamino)-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-71-4 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-72-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-mannopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-73-6 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-allopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-74-7 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-phosphono-D-galactopyranosyl)amino]hexyl]-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-75-8 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-β-D-glucopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-76-9 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-α-D-galactopyranosyl-D-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)




RN 168752-77-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetamino)-2-deoxy-3-O-β-D-galactopyranosyl-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3α,4β,6α)]- (9CI) (CA INDEX NAME)



RN 168752-78-1 CAPLUS
 CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-β-D-galactopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
50.89	384.53

SINCE FILE	TOTAL
ENTRY	SESSION
-3.65	-4.38

STN INTERNATIONAL LOGOFF AT 12:44:00 ON 05 DEC 2005